The toxicologic evaluation of the hematopoietic system is part of most preclinical and clinical safety studies and has become routine in monitoring a variety of novel and conventional therapies in humans and animals. As with spontaneous disease, iatrogenic blood dyscrasias may be primary but are frequently secondary to other tissue toxicity. The latter tendency makes this easily accessible tissue particularly useful in monitoring for systemic toxicity, while primary hematotoxicity ranks with liver and kidney effects as important and often limiting complications. Although the principles driving the diagnostic approach to spontaneous (clinical) blood disorders generally apply to preclinical and clinical safety studies, there are important differences, particularly regarding control of variables, feasibility of testing, and interpretation of resulting data. The luxury of studying a homogenous population of subjects free of complicating disease under controlled (uniform) laboratory and environmental conditions allows changes to be defined with greater precision and sensitivity. There are generally more options regarding the assays available and frequency of monitoring.
INTRODUCTION
Hematotoxicity is the study of blood and bloodforming tissues as a target organ for drugs, chemicals in the environment or workplace, and factors such as stress, exercise, and ionizing radiation. This article will review some of the principles of this dynamic subspecialty and, along with the preceding reviews of hematopoiesis and the response of bone marrow to injury, provide an introduction and background for the articles that follow. Although these principles apply to xenobiotic-induced hematotoxicity in general, the emphasis will be on issues relating to drug development and preclinical safety evaluation.
BLOOD AS A TARGET ORGAN
Blood and hematopoietic tissue rank with liver and kidney as target organs worthy of careful scru-tiny in preclinical and clinical safety evaluations. Factors contributing to this include the high mitotic rate of hematopoietic tissue, the exposure of blood cells to agents administered systemically, and the consequences of blood cell damage and bone marrow impairment.
In normal individuals, red cells, platelets and neutrophils are each produced at a rate of approximately 1-3 million/sec (7) . When demand for cells is high, as in disorders such as hemolytic anemia or suppurative inflammation, this rate can be increased up to 8-fold (11) . Like other rapidly dividing tissue, such as intestine and gonads, bone marrow is particularly sensitive to several classes of drugs and nontherapeutic chemicals. For example, cytopenia is often the limiting toxicity defining treatment regimens that include cytoreductive (anticancer, immunosuppressive) agents and radiotherapy. The marrow can also be a therapeutic target for agents designed to stimulate blood cell production or protect against the aforementioned myelotoxicity (9, 22) . The latter agents (recombinant cytokines, syn-thetic peptides, etc.) present novel and interesting much less acceptable for an antihypertensive or anhematotoxic liabilities (20) , as discussed in subsetiinflammatory agent, where the target disease is less quent presentations. serious, or when less toxic alternatives are available. Blood cells are exposed to any agent absorbed or The acceptable risk: benefit ratio is not always clear injected into the bloodstream, even those rapidly or widely agreed upon, whether the effect represents metabolized and excreted. They sustain a particu-&dquo;exaggerated pharmacology,&dquo; such as the bleeding larly high level of exposure to drugs administered associated with some antithrombotic and thromparenterally, just after injection and prior to dilution bolytic agents (2, 5) , or is unrelated to the action of within the intravascular compartment and equili-the drug, as in the agranulocytosis associated with bration with other tissues. This is the rationale for the tricyclic antidepressant agents (14) . In the latter requiring &dquo;blood compatibility&dquo; testing, where cancase, the rather high incidence of this life-threatdidate parenteral drugs are tested in vitro at high ening complication (12) has provoked controversy concentrations for direct effects on red cells and pro-and extraordinary measures to monitor for this eftein constituents.
fect. Complicating the issue of risk: benefit even The consequences of bone marrow impairment more is the recent and legitimate concern for exor direct damage to blood cells leading to cytopenia posure to the human immunodeficiency virus via or dysfunction can be extensive and serious. The transfusion. Thus, moderate anemia manageable by obvious sequellae include anoxia due to anemia, transfusion is regarded as a less acceptable toxicity infection and sepsis following leukopenia, and hemtoday, even in patients being treated for life-threatorrhage associated with thrombocytopenia and co-ening diseases, because of this new threat. agulopathies. These changes can be dramatic or sub-The predictive value of data from preclinical safetle and present with a host of secondary and ty and toxicity studies for hematotoxicity in humans compensatory changes in hematopoietic and extra-is another controversial issue. Although there are medullary tissues, as reviewed by Dr. Rebar in the substantial species differences in some hematologic preceding manuscript and the papers that follow.
parameters, such as red cell life span and metabo-
The association of an experimental drug with a lism, leukocyte distribution and kinetics, and cer-&dquo;blood dyscrasia&dquo; can sometimes present an insurtain aspects of coagulation and platelet function, the mountable stigma that exceeds the actual toxicolfundamentals of oxygen transport, phagocytic funcogic significance of the effect. tion, hemostasis, and hematopoiesis are generally Hematotoxicity can be divided into primary and conserved across species, and differences usually resecondary hematologic effects. Although the incilate more to the relative sensitivity to the offending dence of primary iatrogenic (drug-induced) blood drug and the metabolism of the agent. In the few dyscrasias in human patients is not clearly under-studies in which relative sensitivity has been sysstood and difficult to assess, it is widely regarded as tematically examined across a therapeutic group, among the more common serious adverse effects of wide variability among species has been observed. drug therapy (16) . In a study reported by Danielson Marsh (18) studied the relative hematotoxic potenet al (6) , hospitalized patients in a health cooperative tial of several antineoplastic agents in animal modgroup were followed over a period in which ap-els commonly used to screen for these effects. The proximately 1.5 million prescriptions per year were sensitivity varied substantially among the species, filled. Anticancer drugs accounted for 61 °lo of the and the order was not predictable. He did observe, drug-induced hematotoxicity. Excluding these pa-however, a good correlation between in vitro obtients, as well as patients suffering chronic alcohol-servations (granulocyte-macrophage colony-formism, severe liver or renal disease (such as viral hep-ing units) and myelosuppression in vivo. Nor are atitis), infectious mononucleosis, disorders requiring there data to support the widely held contention that transfusions, familial problems, or other conditions species phylogenetically closer to humans (i.e., the associated with hematopathology, only 1 per 100,000 monkey) are more predictive as models for hemahad demonstrable drug-induced hematotoxicity. The totoxicity in human patients. The advantage of uspreceding exclusions, together with the focus on hosing a species in which the drug is pharmacologically pitalized patients, make this a very conservative active, however, is an obvious one: to study the estimate if one projects to the population at large. potential hematotoxic effects of hyperpharmacolo-Like other organ toxicity, primary hematotoxicity gy. Studies on human recombinant granulocyte colis assessed in the context of risk versus benefit. In ony-stimulating factor provide such an example, many anticancer and antiviral treatment regimens, where the dog proved to be a practical model in hematotoxicity is often limiting. As such, it is not which the recombinant human protein was shown only tolerated but defines the dose appropriate for to be active (10) . the patient. At the same time, hematotoxicity is Primary hematotoxicity can be selective, affecting primarily the blood or bone marrow, or nonspecific.
Examples of a selective effect include chloramphenicol-induced red cell aplasia (17), clozapine-induced agranulocytosis (13) , and gold-induced immune thrombocytopenia (1) . There is evidence for genetic predisposition to some of these iatrogenic disorders (4, 15) . These, in general, are less predictable and more often idiosyncratic or population-specific than agents that have a relatively nonspecific cytotoxic or antimitotic effect, such as anticancer and immunosuppressive drugs, where any rapidly dividing population of cells (bone marrow, gonads, intestinal mucosa, etc.) is at risk. The latter agents have a hematotoxic potential that is often better defined, more manageable, and more easily justified in the context of risk : benefit. As with other toxicity, a low incidence or idiosyncratic hematotoxic effect in man, such as cephalosporin-induced immune cytopenia, can sometimes be expressed at a higher incidence in animal models treated with large doses of the agent (3). Secondary hematotoxicity, or hematologic effects secondary to other organ damage or dysfunction, is the most common hematotoxicity observed in the clinic and toxicology laboratory. Anemia of chronic (inflammatory) disease is among the most common anemias observed in humans (19) and animals (8) . Red cell morphologic changes associated with thrombotic disease; quantitative and morphologic changes in circulating leukocytes during sepsis, allergy, and other disorders; and alterations in bone marrow cellularity and maturation patterns associated with azotemia are all examples of secondary changes. The propensity of blood cells to reflect such a wide range of local and systemic effects of drugs, along with the accessibility of blood, is why this tissue is so carefully monitored during toxicity and safety studies. It also explains why hematotoxicology so often falls within the domain of the clinical pathologist. Thus, the importance of this target organ system in toxicology stems not only from the toxicologic significance of hematotoxic effects, but also from the diagnostic utility of these changes.
TOXICOLOGIC HEMATOPATHOLOGY
Although the principles of clinical hematology, as applied to managing human and veterinary patients with spontaneous disease, generally apply to the toxicologic assessment of a candidate drug or chemical product, a few major differences profoundly affect the way we as toxicologic pathologists can detect and interpret hematologic effects. These include our ability to manage or control confounding variables that occur in clinical practice, the feasibility of testing, the availability of sophisticated diagnostic tools, the approach to testing, and the data base established for each human or animal subject.
In a clinical setting, variables such as diet, environmental factors, and concurrent disease can be confounding and compromise the precision and predictive value of the tests we use to detect hematologic effects. For example, small changes in the mean corpuscular volume in a laboratory beagle or rat can be far more meaningful than those observed in a hospital setting (21 ) . The use of control populations, reference ranges specific for the subjects studied, and the availability of pretreatment data further increase the sensitivity and predictive value of such testing. Sophisticated testing is often more feasible, in that the toxicologist can usually schedule the event and more easily justify the application of costly technology such as flow cytometry and bone marrow stem cell culture assays. Moreover, the protocol usually entails regular pretreatment and interim screening, which defines more precisely the initiation and course of the hematologic effect. The extensive clinicopathologic data base available, together with information on drug distribution and metabolism in the subjects under study, further enhance the ability of the toxicologist to interpret subtle effects.
Monitoring for hematotoxicity in a toxicology laboratory can be divided into core (routine) tests (Table I) and special (problem-driven) assays (Table  II) . What constitutes &dquo;routine&dquo; monitoring is sometimes technology-driven. For example, most laboratories use automated hematology analyzers that provide platelet counts as part of the complete blood count. Consequently, this measure has become routine. The reticulocyte count now appears to be making that transition, as automation of that assay also becomes widespread. Whether or not this index of erythrogenesis should be used to routinely screen for toxicity, rather than as a problem-driven measure to characterize anemia (as this author believes), is controversial. The core tests listed in Table I (23) , with the exception of bone marrow cytologic preparations; the Task Force recommended that, in the absence of indications of potential hematotoxicity, marrow smears be collected but only evaluated when a hematologic effect was evidenced by other clinical or laboratory data. Bone marrow sections also were not listed but were assumed to be among the tissues collected in routine histologic surveys.
Examples of how these data are used to characterize hematotoxicity and toxicologic mechanisms will be discussed in the papers that follow. What is worthy of emphasis in this introductory discussion, however, is the importance of taking advantage of the resources uniquely available to the toxicologic pathologist when interpreting treatment-related changes. For example, an observation made on a bone marrow smear should always be interpreted in the context of peripheral blood data (cell counts and morphologic assessment) and histology (bone marrow sections). Too often these evaluations are assigned to separate professionals (the medical technologist, clinical pathologist, and histopathologist, respectively), and the observations are inadequately correlated. Unlike our colleagues in the clinic, the toxicologic pathologist usually has the luxury of assembling pretreatment and interim peripheral blood data, peripheral blood and bone marrow smears, and bone marrow sections when evaluating a hematologic effect. The relative and unique contributions of bone marrow sections, relative to cytologic preparations, and examples of how these can be applied have been discussed previously.
INTERPRETATION OF DATA
Evaluation of hematologic data in a toxicology laboratory entails assessment of the quality of data. This task relates to quality assurance issues: use of standards, assessment of precision and accuracy, validation procedures, etc. This important area will not be addressed here. In contrast, interpretation of the data relates to the meaning or, in this case, the toxicologic significance of the observation. This is (or should be) accomplished using data from control populations, pretreatment and interim observations (subjects as their own controls), reference ranges relevant to the population studied, and, finally, the principles of pathology and internal medicine.
Comparison with data from control populations evokes the use of statistics, an important but muchabused tool for interpreting data in this field. Statistical analyses (e.g., trend analyses) can also be applied to individual groups when pretreatment and interim data are available. Having data that allow subjects to be used as their own controls is partic- ularly important when interpreting individual animal effects. Reference ranges specific to the species, strain, age, sex, laboratory environment, and methodology employed provide another important comparator that shapes the context in which treatment-related effects are interpreted. Finally, a change may be clearly demonstrable and statistically significant yet hold little biologic or toxicologic significance. This is particularly true of this organ system, which is more thoroughly scrutinized and reflects events elsewhere in the body with such sensitivity. Providing this level of interpretation, based on the principles of toxicologic pathology and knowledge of the biology of the subjects studied, distinguishes the role of the toxicologic pathologist from that of the statistician and computer scientist.
